Annual Information Update

RNS Number : 6727J
Oxford Biomedica PLC
01 April 2010
 



For Immediate Release

1 April 2010

 

 

Oxford BioMedica plc ("Oxford BioMedica" or the "Company")

 

Annual Information Update for the Twelve Months to 1 April 2010

 

Oxford BioMedica is providing an annual information update pursuant to Prospectus Rule 5.2 made by the Financial Services Authority.

 

1.                   Announcements made via a Regulatory Information Service

 

Date                    

Announcement



14 April 2009

Holding(s) in Company

17 April 2009

Holding(s) in Company

29 April 2009

New development collaboration with Sanofi-aventis for ocular diseases

29 April 2009

Termination of development collaboration for TroVax

1 May 2009

Holding(s) in Company

11 May 2009

Update on patent infringement litigation

14 May 2009

Interim management statement

28 May 2009

Blocklisting interim review

29 May 2009

Total voting rights update

1 June 2009

Update on Phase I/II and II TroVax clinical trials

4 June 2009

AGM result

18 June 2009

Corporate presentation at Piper Jaffray Europe conference

18 June 2009

Holding(s) in Company

19 June 2009

Holding(s) in Company (amendment)

6 July 2009

Outcome of FDA review of TroVax

13 July 2009

ProSavin clinical trial update

5 August 2009

Notice of interim results

6 August 2009

Analyst meeting - change of time

7 August 2009

Corporate presentation at Canaccord Adams Global Growth Conference

19 August 2009

Notice that TroVax Phase III data will be presented at ECCO/ESMO conference

27 August 2009

Interim results

28 August 2009

Total voting rights update

1 September 2009

Director's interest in shares

4 September 2009

Corporate presentation at Rodman & Renshaw conference

22 September 2009

TroVax Phase III data presented at ECCO/ESMO conference

30 September 2009

Total voting rights update

15 October 2009

ProSavin clinical trial update

19 October 2009

Holding(s) in Company

30 October 2009

Total voting rights update

19 November 2009

Interim management statement

27 November 2009

Blocklisting interim review

3 December 2009

Holding(s) in Company

15 December 2009

Orphan Drug designation granted for StarGen in Europe

5 January 2010

Management and Board changes

20 January 2010

Orphan Drug designation granted for UshStat in Europe

22 January 2010

Purchase of patent rights and issue of shares

27 January 2010

Settlement of patent litigation with Bavarian Nordic

27 January 2010

Extension of research collaboration in motor neurone disease

29 January 2010

Total voting rights update

17 February 2010

Notice of results

26 February 2010

Total voting rights update

10 March 2010

Preliminary results for 2009

29 March 2010

2009 annual report & accounts and AGM notification

31 March 2010

Total voting rights update

1 April 2010

Annual information update

 

 

Details of all regulatory announcements for Oxford BioMedica can be found on the London Stock Exchange website at www.londonstockexchange.com  and on the Oxford BioMedica website at http://www.oxfordbiomedica.co.uk 

 

2.                  Documents filed with Companies House

 

Date                     

Document Type       

Description




4 June 2009

AGM Special Business

AGM minutes

18 September 2009

88(2) Return of Allotment of shares

Allotment 1,658,052 1p Ord.

24 September 2009

363a Annual Return

Annual return

7 December 2009

SH01 Return of Allotment of shares

Allotment 28,973 1p Ord.

 

Copies of documents filed at Companies House can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ or through Companies House Direct at www.direct.companieshouse.gov.uk 

 

3.                  Documents published or sent to shareholders or filed with the UKLA Viewing Facility

 

Date                    

Description

9 September 2009

Interim Report for 6 months to 30 June 2009

29 March 2010

Annual report for the year ended 31 December 2009

 

 

Copies of all the above documents may be obtained from the Company Secretary at the Company's Registered Office:

 

This annual information update is filed pursuant to Prospectus Rule 5.2 made by the Financial Services Authority and not for any other purpose and by filing this annual information update neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained or referred to below herein. The information referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to below constitutes, by virtue of this communication, an offer of any securities addressed to any person and should not be relied on by any person.

 

 

 

Oxford BioMedica plc

Medawar Centre

Robert Robinson Avenue

The Oxford Science Park

Oxford

OX4 4GA

 

1 April 2010


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

AIUZFLFBBZFEBBF